| Semax is a new heptapeptide nootropic that shares a similar history, potency and chemical make-up with Noopept powder. Semax was developed in 1982 by a research team from the Institute of Molecular Genetics at the Russian Academy of Sciences in Moscow. It was initially pursued as a treatment for stroke victims suffering bran damage but was subsequently determined to promote significant cognitive enhancement in health individuals as well. This nootropic sti |